MX2020004883A - Composiciones de exosomas modificados y metodos de cargar cargas de exosomas luminales. - Google Patents

Composiciones de exosomas modificados y metodos de cargar cargas de exosomas luminales.

Info

Publication number
MX2020004883A
MX2020004883A MX2020004883A MX2020004883A MX2020004883A MX 2020004883 A MX2020004883 A MX 2020004883A MX 2020004883 A MX2020004883 A MX 2020004883A MX 2020004883 A MX2020004883 A MX 2020004883A MX 2020004883 A MX2020004883 A MX 2020004883A
Authority
MX
Mexico
Prior art keywords
exosomes
methods
payloads
luminal
loading
Prior art date
Application number
MX2020004883A
Other languages
English (en)
Inventor
Kevin P Dooley
Russell E Mcconnell
Ke Xu
Sonya Haupt
John D Kulman
Douglas E Williams
Rane A Harrison
Damian J Houde
Madeleine Youniss
Original Assignee
Codiak Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Codiak Biosciences Inc filed Critical Codiak Biosciences Inc
Publication of MX2020004883A publication Critical patent/MX2020004883A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5184—Virus capsids or envelopes enclosing drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C12N2509/10—Mechanical dissociation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Botany (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Dispersion Chemistry (AREA)
  • Reproductive Health (AREA)

Abstract

La presente invención se refiere a métodos para preparar un exosoma terapéutico usando proteínas recientemente identificadas para ser enriquecidas en el lumen de exosomas. Específicamente, la presente invención proporciona métodos para localizar una proteína o péptido terapéutico en exosomas. Los métodos implican la generación de exosomas modificados en el lumen que incluyen una o más de las proteínas de exosoma a concentraciones mayores, una modificación o un fragmento de la proteína de exosoma, o una proteína de fusión de la proteína de exosoma y una proteína terapéutica o de carga.
MX2020004883A 2017-11-17 2018-11-16 Composiciones de exosomas modificados y metodos de cargar cargas de exosomas luminales. MX2020004883A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762587767P 2017-11-17 2017-11-17
US201862634750P 2018-02-23 2018-02-23
PCT/US2018/061679 WO2019099942A1 (en) 2017-11-17 2018-11-16 Compositions of engineered exosomes and methods of loading luminal exosomes payloads

Publications (1)

Publication Number Publication Date
MX2020004883A true MX2020004883A (es) 2020-08-06

Family

ID=66534134

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004883A MX2020004883A (es) 2017-11-17 2018-11-16 Composiciones de exosomas modificados y metodos de cargar cargas de exosomas luminales.

Country Status (11)

Country Link
US (3) US20190151456A1 (es)
JP (2) JP2021503300A (es)
KR (2) KR20250005239A (es)
CN (2) CN120204412A (es)
AR (1) AR115159A1 (es)
AU (1) AU2018367670A1 (es)
CA (2) CA3082588A1 (es)
IL (1) IL274634A (es)
MX (1) MX2020004883A (es)
SG (1) SG11202003871SA (es)
WO (1) WO2019099942A1 (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12364661B2 (en) 2015-11-20 2025-07-22 The Regents Of The University Of California Deformable nano-scale vehicles (DNVS) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery
WO2019060629A1 (en) * 2017-09-21 2019-03-28 Codiak Biosciences, Inc. PRODUCTION OF EXTRACELLULAR VESICLES IN A SUSPENSION OF INSULATED CELLS USING CHEMICALLY DEFINED CELL CULTURE MEDIA
US20220017907A1 (en) * 2017-11-17 2022-01-20 Codiak Biosciences, Inc. Engineered extracellular vesicles and uses thereof
US12066382B2 (en) 2018-06-21 2024-08-20 Lonza Sales Ag Methods of measuring extracellular vesicles and nanoparticles in complex matrices by light scattering
SMT202200156T1 (it) * 2018-11-16 2022-05-12 Codiak Biosciences Inc Vescicole extracellulari ingegnerizzate e loro usi
SG11202108389QA (en) * 2019-02-04 2021-08-30 Codiak Biosciences Inc Membrane protein scaffolds for exosome engineering
KR20220009389A (ko) * 2019-04-17 2022-01-24 코디악 바이오사이언시즈, 인크. 엑소좀 및 aav 의 조성물
WO2020231700A1 (en) * 2019-05-11 2020-11-19 Youngsuk Yi Neurotoxin compositions and methods
US20220251200A1 (en) 2019-07-03 2022-08-11 Codiak Biosciences, Inc. Extracellular vesicles targeting t cells and uses thereof
EP4013875A1 (en) * 2019-08-14 2022-06-22 Codiak BioSciences, Inc. Extracellular vesicles with stat3-antisense oligonucleotides
US20230002764A1 (en) 2019-08-14 2023-01-05 Codiak Biosciences, Inc. Extracellular vesicle-aso constructs targeting cebp/beta
EP4470619A3 (en) 2019-08-14 2025-04-23 Lonza Sales AG Extracellular vesicle-aso constructs targeting stat6
CN114641570A (zh) * 2019-08-14 2022-06-17 科迪亚克生物科学公司 具有靶向kras的反义寡核苷酸的细胞外囊泡
WO2021030777A1 (en) * 2019-08-14 2021-02-18 Codiak Biosciences, Inc. Extracellular vesicle linked to molecules and uses thereof
WO2021030773A1 (en) 2019-08-14 2021-02-18 Codiak Biosciences, Inc. Extracellular vesicle-nlrp3 antagonist
US20230241089A1 (en) 2019-09-25 2023-08-03 Codiak Biosciences, Inc. Sting agonist comprising exosomes for treating neuroimmunological disorders
WO2021062057A1 (en) 2019-09-25 2021-04-01 Codiak Biosciences, Inc. Exogenous loading of exosomes via lyophilization
US20240099973A1 (en) 2019-09-25 2024-03-28 Lonza Sales Ag Extracellular vesicle compositions
EP4034276A1 (en) 2019-09-25 2022-08-03 Codiak BioSciences, Inc. Methods of producing extracellular vesicles
EP4034150A1 (en) 2019-09-25 2022-08-03 Codiak BioSciences, Inc. Sting agonist comprising exosomes combined with il-12 displaying exosomes for treating a tumour
WO2021092193A1 (en) 2019-11-05 2021-05-14 Codiak Biosciences, Inc. High-throughput chromatography screening for extracellular vesicles
WO2021146616A1 (en) 2020-01-17 2021-07-22 Codiak Biosciences, Inc. Cholesterol assays for quantifying extracellular vesicles
US20230097907A1 (en) * 2020-01-27 2023-03-30 Mantra Bio, Inc. Non-naturally occurring vesicles comprising a chimeric vesicle localization moiety, methods of making and uses thereof
AU2021215935A1 (en) 2020-02-05 2022-08-25 Diadem Biotherapeutics Inc. Artificial synapses
WO2021175289A1 (zh) * 2020-03-04 2021-09-10 中国科学院遗传与发育生物学研究所 多重基因组编辑方法和系统
WO2021184017A1 (en) 2020-03-13 2021-09-16 Codiak Biosciences, Inc. Extracellular vesicles for treating neurological disorders
WO2021184020A1 (en) 2020-03-13 2021-09-16 Codiak Biosciences, Inc. Methods of treating neuroinflammation
WO2021184021A1 (en) 2020-03-13 2021-09-16 Codiak Biosciences, Inc. Extracellular vesicle-aso constructs targeting pmp22
AU2021236763A1 (en) 2020-03-20 2022-10-06 Lonza Sales Ag Extracellular vesicles for therapy
CA3178252A1 (en) 2020-05-11 2021-11-18 Erytech Pharma Red cell extracellular vesicles (rcevs) containing cargoes and methods of use and production thereof
WO2021248133A1 (en) 2020-06-05 2021-12-09 Codiak Biosciences, Inc. Anti-transferrin extracellular vesicles
KR20230042754A (ko) * 2020-08-07 2023-03-29 아미쿠스 세라퓨틱스, 인코포레이티드 소포 표적화 단백질 및 이의 용도
US20250249072A1 (en) 2020-08-17 2025-08-07 Lonza Sales Ag Methods of treating cancer
US20240241020A1 (en) 2020-09-23 2024-07-18 Lonza Sales Ag Process for preparing extracellular vesicles
CA3192470A1 (en) 2020-09-23 2022-03-31 Tim SOOS Methods of producing extracellular vesicles
WO2022066883A1 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Extracellular vesicles comprising kras antigens and uses thereof
EP4217087A2 (en) 2020-09-23 2023-08-02 Codiak BioSciences, Inc. Process for preparing extracellular vesicles
WO2022076596A1 (en) 2020-10-06 2022-04-14 Codiak Biosciences, Inc. Extracellular vesicle-aso constructs targeting stat6
CN112410304A (zh) * 2020-11-12 2021-02-26 天津大学 一种基因修饰的外泌体及其制备方法和应用
CN112903999A (zh) * 2021-01-20 2021-06-04 蚌埠医学院第一附属医院（蚌埠医学院附属肿瘤医院） 一种用于纳米流式细胞仪检测的外泌体的制备方法及应用
CN117177739A (zh) 2021-02-17 2023-12-05 隆萨销售股份有限公司 负载细胞外囊泡的方法
EP4294421A2 (en) 2021-02-17 2023-12-27 Lonza Sales AG Extracellular vesicle-nlrp3 antagonist
KR20230166101A (ko) 2021-04-01 2023-12-06 론자 세일즈 아게 세포외 소포 조성물
CN115505599A (zh) * 2021-06-23 2022-12-23 艾威亚(广州)医药科技有限公司 Gpi诱导的胰岛素靶向型外泌体的制备及其在递送重组生物药物中的应用
JPWO2023027082A1 (es) * 2021-08-23 2023-03-02
KR20240082391A (ko) 2021-10-14 2024-06-10 론자 세일즈 아게 세포외 소포 생산을 위한 변형된 생산자 세포
WO2023085821A1 (ko) * 2021-11-10 2023-05-19 주식회사 씨케이엑소젠 엑소좀 기반 항바이러스 백신 및 이의 제조방법
WO2023091905A1 (en) * 2021-11-19 2023-05-25 Elmaleh David R Targeted extracellular vesicles and methods of use thereof
WO2023183794A2 (en) * 2022-03-24 2023-09-28 Mercury Bio, Inc. Direct production of sirnas in saccharomyces boulardii and packaging in extracellular vesicles (evs) for targeted gene silencing
CN117126886A (zh) * 2022-05-20 2023-11-28 谛邈生物科技(北京)有限公司 一种实现工程化EVs功能蛋白模块化装载的核酸构建体及其应用
CN115073611B (zh) * 2022-06-21 2025-10-21 中国人民解放军空军军医大学 一种便于选择性捕获功能外泌体及其纯化方法和应用
CN116656705A (zh) * 2023-04-18 2023-08-29 河南中医药大学第一附属医院 pHLIP-Lamp2b-1/2融合蛋白重组质粒及其构建、应用
WO2025100522A1 (ja) * 2023-11-10 2025-05-15 公立大学法人大阪 ポリペプチド、融合タンパク質、融合タンパク質の製造方法、エクソソームにタンパク質を局在化させる方法、エクソソーム、及びエクソソームの製造方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1412498A2 (en) * 2001-07-17 2004-04-28 Novartis AG Polynucleotides expressed in dendritic cells and polypeptides encoded thereby
US20130053426A1 (en) * 2009-04-17 2013-02-28 Yiqi Seow Composition For Delivery Of Genetic Material
CN103002879B (zh) * 2010-07-01 2016-04-20 阿昂梅迪克斯公司 来自细胞原生质体的微泡及其应用
GB201121069D0 (en) * 2011-12-07 2012-01-18 Isis Innovation Delivery system
WO2016172598A1 (en) * 2015-04-22 2016-10-27 The Broad Institute Inc. Exosomes and uses thereof
US10624849B2 (en) * 2015-09-28 2020-04-21 Northwestern University Targeted extracellular vesicles comprising membrane proteins with engineered glycosylation sites
AU2016381513A1 (en) * 2015-12-30 2018-07-19 The Regents Of The University Of California Methods for enhanced production and isolation of cell-derived vesicles
WO2017147719A1 (en) * 2016-03-04 2017-09-08 Exerkine Corporation Method for treating neuropathy

Also Published As

Publication number Publication date
WO2019099942A1 (en) 2019-05-23
CN120204412A (zh) 2025-06-27
CN111511384B (zh) 2025-03-04
US20190151456A1 (en) 2019-05-23
SG11202003871SA (en) 2020-05-28
CN111511384A (zh) 2020-08-07
AR115159A1 (es) 2020-12-02
KR20250005239A (ko) 2025-01-09
KR20200091390A (ko) 2020-07-30
CA3234784A1 (en) 2019-05-23
AU2018367670A1 (en) 2020-05-07
IL274634A (en) 2020-06-30
JP2021503300A (ja) 2021-02-12
US20240000944A1 (en) 2024-01-04
JP2024015074A (ja) 2024-02-01
CA3082588A1 (en) 2019-05-23
US20200347112A1 (en) 2020-11-05

Similar Documents

Publication Publication Date Title
MX2020004883A (es) Composiciones de exosomas modificados y metodos de cargar cargas de exosomas luminales.
CL2021001278A1 (es) Vesículas extracelulares modificadas y sus usos
CL2020003071A1 (es) Proteínas de unión multiespecíficas y mejoras con estas
CL2020000428A1 (es) Preparación de exosomas terapéuticos mediante el uso de proteínas de membrana.
CY1124106T1 (el) Συνθεσεις μεταφορεα-αντισωματος και μεθοδοι παρασκευης και χρησης αυτων
MX2021003939A (es) Inhibidores de la interaccion de menina-leucemia de linaje mixto.
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
CY1123963T1 (el) Καινοτομα πολυμερικα προφαρμακα hgh
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
MX2016009428A (es) Proteinas de union a calicreina en plasma y usos de las mismas para tratar el angioedema hereditario.
MX2018011491A (es) Disposiciones de secuencia y secuencias para presentacion de neoepitopos.
MX2016013457A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
CL2017000311A1 (es) Anticuerpos anti-lag3 y fragmentos de unión a antígeno
ECSP18096095A (es) Anticuerpos a la alfa-sinucleína y usos de los mismos
BR112016027773A2 (pt) peptídeo célula-penetrante, polinucleotídeo, proteína recombinante célula penetrante de toxina botulínica, vetor de expressão recombinante, bactéria, composição farmacêutica, composição cosmética e método para produzir uma proteína recombinante célula-penetrante de toxina botulínica
BR112017016019A2 (pt) método para tratamento de câncer, artigo para fabricação, e, kit.
CL2017001883A1 (es) Compuestos antisenescentes y usos de los mismos
MX2018010415A (es) Composiciones y metodos para inmunoterapia de grupo de diferenciacion 20 (cd20).
SV2018005714A (es) Composiciones y metodos para disminuir la expresion de tau
MX2016016301A (es) Procesos de siembra en serie y usos de los mismos.
MX359201B (es) Polipeptidos que se unen al complemento humano 5 (c5).
MX2017007256A (es) Inhibidor de bromodominio como adyuvante en la inmunoterapia contra el cancer.
CL2015001446A1 (es) Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido.
CL2023000892A1 (es) Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b (divisional).
MX2021002292A (es) Terapias de combinacion que comprenden proteinas quimericas basadas en sirp alfa.